Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

Medicago begins human testing of flu vaccine

Medicago Inc. (TSX-V: MDG) announced a Phase I trial for its H5N1 Avian Influenza vaccine. The Phase I study will evaluate safety, tolerability and the immune response of the Company’s H5N1 vaccine candidate in 48 healthy volunteers between the ages 18 to 60. Results of the study are expected during the fourth quarter of 2009. Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Provectus starts Phase 1 trial for liver cancer treatment

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) has initiated a Phase 1 study of PV-10 for liver cancer that will enroll up to six subjects with cancer metastatic to the liver or with recurrent liver cancer. PV-10 is the company’s lead oncology drug candidate that is also currently undergoing Phase 2 study for metastatic melanoma. The primary objective of the study is to determine the safety and tolerability of a single intralesional injection of PV-10 in patients Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

XOMA to initiate Phase 2 program for Type 2 Diabetes and Cardiovascular Disease

XOMA Ltd. (Nasdaq:XOMA) announced plans for the Phase 2 clinical development of its anti-inflammatory drug candidate to interleukin-1 beta (IL-1 beta), XOMA 052, designed for the treatment of the inflammatory cause of cardiovascular, diabetes, autoimmune and other diseases. The clinical trials are designed to further evaluate the use of multiple dose regimens on the safety, pharmacodynamics and efficacy of XOMA 052 in cardiometabolic and other diseases, and based on positive results, select doses for pivotal Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

U.S. Navy to fund Vical’s H1N1 vaccine

The U.S. Navy has awarded a contract for $1.25 million to Vical Incorporated (Nasdaq:VICL) for large-scale cGMP vaccine manufacturing and related clinical and regulatory preparations, which are already underway, for a Phase 1 clinical trial of the company’s vaccine against A/H1N1 pandemic influenza. The trial will be conducted in collaboration with the U.S. Naval Medical Research Center. Vical was the first company to produce a vaccine against the A/H1N1 influenza virus after the initial reports Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Hana Biosciences’ clinical trial agreement with the National Cancer Institute

Hana Biosciences (OTCBB:HNAB) announced a Clinical Trial Agreement with the Center for Cancer Research (CCR) at the National Cancer Institute for the co-development of Marqibo(R) (vincristine sulfate liposomes injection) in refractory pediatric cancer. The five-year agreement will initially focus on a Phase 1 trial to evaluate the safety, preliminary efficacy, pharmacokinetic profile, and weekly dose of Marqibo in children and adolescents with refractory cancer. Following the Phase I trial, the Company and CCR plan a Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,